CB-5083

p97/VCP ATPase inhibitor (PDE6 off-target)

Ph. I in cancer (discont., dyschromatopsia)

from HTS of NIH compound library

J. Pharmacol. Exp. Ther., Apr. 30, 2021

Cleave Therapeutics, San Francisco, CA

The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.